KROS
Keros Therapeutics, Inc.
Price Chart
Latest Quote
$10.41
-0.52 (-4.76%)
Current Price
| Previous Close | $10.93 |
| Open | $10.94 |
| Day High | $11.11 |
| Day Low | $10.38 |
| Volume | 267,054 |
Stock Information
| Shares Outstanding | 19.79M |
| Total Debt | $16.31M |
| Cash Equivalents | $281.50M |
| Revenue | $33.18M |
| Net Income | $-85.14M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $206.03M |
| EPS (TTM) | $-2.53 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-49.06M |
| Sales | $33.18M |
| Income | $-85.14M |
| Book/sh | $14.47 |
| Cash/sh | $14.22 |
| Employees | 87 |
Financial Ratios
| Quick Ratio | 22.17 |
| Current Ratio | 22.61 |
| Debt/Eq | 5.71 |
Returns & Margins
| ROA | -12.23% |
| ROE | -16.79% |
| Gross Margin | -184.89% |
| Operating Margin | -7050.95% |
| Profit Margin | -256.60% |
Ownership
| Insider Ownership | 3.72% |
| Institutional Ownership | 96.24% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.86 |
| P/S | 6.21 |
| P/B | 0.72 |
Analyst Data
| Recommendation | none |
| Target Price | $21.83 |
Technical Indicators
| SMA20 | $10.52 |
| SMA50 | $11.03 |
| SMA200 | $14.88 |
| RSI | 44.12 |
| ATR | 0.5069 |
| Shares Float | 17.80M |
| Short Float | 8.77% |
| Short Ratio | 4.38 |
| Volatility | 0.96 |
| Rel Volume | 1.14 |
Performance History
| Week | +0.00% |
| Month | -7.30% |
| Quarter | -8.20% |
| 6 Months | -51.22% |
| YTD | -43.85% |
| Year | -24.07% |
| 3 Years | -73.61% |
| 5 Years | -80.19% |
| 10 Years | -48.16% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $10.41 | 267,054 |
| 2026-06-24 | $10.92 | 212,800 |
| 2026-06-23 | $11.00 | 268,000 |
| 2026-06-22 | $10.98 | 340,500 |
| 2026-06-18 | $10.65 | 400,500 |
| 2026-06-17 | $10.41 | 241,800 |
| 2026-06-16 | $10.03 | 264,400 |
| 2026-06-15 | $10.24 | 347,400 |
| 2026-06-12 | $10.15 | 178,200 |
| 2026-06-11 | $10.05 | 232,500 |
| 2026-06-10 | $9.93 | 190,400 |
| 2026-06-09 | $10.07 | 196,800 |
| 2026-06-08 | $10.00 | 169,400 |
| 2026-06-05 | $10.30 | 163,500 |
| 2026-06-04 | $10.77 | 155,900 |
| 2026-06-03 | $10.50 | 190,500 |
| 2026-06-02 | $10.55 | 310,900 |
| 2026-06-01 | $10.90 | 231,900 |
| 2026-05-29 | $11.25 | 162,900 |
| 2026-05-28 | $11.39 | 172,500 |
| 2026-05-27 | $11.31 | 224,500 |
| 2026-05-26 | $11.23 | 480,500 |
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-Ã signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
đ° Latest News
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
Zacks âĸ 2026-05-22T15:10:00Z
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
Zacks âĸ 2026-05-22T15:06:00Z
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
Zacks âĸ 2026-05-22T15:03:00Z
Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20
Simply Wall St. âĸ 2026-05-17T13:36:32Z
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
Zacks âĸ 2026-05-15T16:08:00Z
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-14T13:10:02Z
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-13T21:35:02Z
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-11T21:10:02Z
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
Zacks âĸ 2026-04-20T15:41:00Z
KROS Rinvatercept: What to Know Before DMD Phase II Starts
Zacks âĸ 2026-04-20T15:29:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $244,061,000 | $3,550,000 | $151,000 | $0 |
| Operating Revenue | $244,061,000 | $3,550,000 | $151,000 | $0 |
| Expenses | ||||
| Total Expenses | $176,492,000 | $213,145,000 | $167,692,000 | $107,709,000 |
| Other Income Expense | $24,328,000 | $22,542,000 | $14,549,000 | $3,031,000 |
| Other Non Operating Income Expenses | $-539,000 | $-954,000 | $-206,000 | $-613,000 |
| Operating Expense | $176,492,000 | $213,145,000 | $167,692,000 | $107,709,000 |
| General And Administrative Expense | $46,849,000 | $40,754,000 | $34,834,000 | $27,525,000 |
| Interest Expense | - | $0 | $0 | $1,000 |
| Net Non Operating Interest Income Expense | - | $0 | $0 | $-1,000 |
| Interest Expense Non Operating | - | $0 | $0 | $1,000 |
| Other Operating Expenses | - | $-1,238,000 | $-2,400,000 | $-7,081,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $87,014,000 | $-187,353,000 | $-152,992,000 | $-104,679,000 |
| Normalized Income | $63,464,951 | $-205,914,840 | $-167,747,000 | $-108,323,000 |
| Net Income From Continuing And Discontinued Operation | $87,014,000 | $-187,353,000 | $-152,992,000 | $-104,679,000 |
| Total Operating Income As Reported | $67,569,000 | $-210,833,000 | $-169,941,000 | $-114,790,000 |
| Net Income Common Stockholders | $87,014,000 | $-187,353,000 | $-152,992,000 | $-104,679,000 |
| Net Income | $87,014,000 | $-187,353,000 | $-152,992,000 | $-104,679,000 |
| Net Income Including Noncontrolling Interests | $87,014,000 | $-187,353,000 | $-152,992,000 | $-104,679,000 |
| Net Income Continuous Operations | $87,014,000 | $-187,353,000 | $-152,992,000 | $-104,679,000 |
| Pretax Income | $91,897,000 | $-187,053,000 | $-152,992,000 | $-104,679,000 |
| Operating Income | $67,569,000 | $-209,595,000 | $-167,541,000 | $-107,709,000 |
| Net Interest Income | - | $0 | $0 | $-1,000 |
| Per Share | ||||
| Diluted EPS | $2.30 | $-5.00 | $-5.20 | $-4.15 |
| Basic EPS | $2.34 | $-5.00 | $-5.20 | $-4.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $1,317,951 | $4,934,160 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $44,211,000 | $-231,862,000 | $-166,932,000 | $-107,648,000 |
| Total Unusual Items | $24,867,000 | $23,496,000 | $14,755,000 | $3,644,000 |
| Total Unusual Items Excluding Goodwill | $24,867,000 | $23,496,000 | $14,755,000 | $3,644,000 |
| Reconciled Depreciation | $1,509,000 | $1,229,000 | $815,000 | $674,000 |
| EBITDA (Bullshit earnings) | $69,078,000 | $-208,366,000 | $-152,177,000 | $-104,004,000 |
| EBIT | $67,569,000 | $-209,595,000 | $-152,992,000 | $-104,678,000 |
| Diluted Average Shares | $37,859,106 | $37,437,652 | $29,447,119 | $23,435,383 |
| Basic Average Shares | $37,221,211 | $37,437,652 | $29,447,119 | $23,435,383 |
| Diluted NI Availto Com Stockholders | $87,014,000 | $-187,353,000 | $-152,992,000 | $-104,679,000 |
| Tax Provision | $4,883,000 | $300,000 | $0 | $0 |
| Gain On Sale Of Security | $24,867,000 | $23,496,000 | $14,755,000 | $3,644,000 |
| Research And Development | $129,643,000 | $173,629,000 | $135,258,000 | $87,265,000 |
| Selling General And Administration | $46,849,000 | $40,754,000 | $34,834,000 | $27,525,000 |
| Other Gand A | $46,849,000 | $40,754,000 | $34,834,000 | $27,525,000 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $303,132,000 | $571,553,000 | $332,213,000 | $277,423,000 |
| Total Assets | $338,021,000 | $615,886,000 | $370,025,000 | $306,781,000 |
| Total Non Current Assets | $22,587,000 | $26,993,000 | $22,732,000 | $21,014,000 |
| Other Non Current Assets | $1,449,000 | $3,505,000 | $3,264,000 | $3,445,000 |
| Current Assets | $315,434,000 | $588,893,000 | $347,293,000 | $285,767,000 |
| Other Current Assets | $2,397,000 | $1,450,000 | $1,001,000 | $276,000 |
| Prepaid Assets | $19,250,000 | $23,056,000 | $14,054,000 | $5,602,000 |
| Receivables | $6,372,000 | $4,456,000 | $1,091,000 | $841,000 |
| Taxes Receivable | $2,250,000 | $0 | - | $0 |
| Accrued Interest Receivable | $555,000 | $1,714,000 | $948,000 | $841,000 |
| Accounts Receivable | $3,567,000 | $2,742,000 | $143,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $287,415,000 | $559,931,000 | $331,147,000 | $279,048,000 |
| Cash And Cash Equivalents | $287,415,000 | $559,931,000 | $331,147,000 | $279,048,000 |
| Debt | ||||
| Total Debt | $16,883,000 | $18,861,000 | $14,444,000 | $13,266,000 |
| Long Term Debt And Capital Lease Obligation | $14,475,000 | $16,883,000 | $13,439,000 | $12,811,000 |
| Current Debt And Capital Lease Obligation | $2,408,000 | $1,978,000 | $1,005,000 | $455,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $34,889,000 | $44,333,000 | $37,812,000 | $29,358,000 |
| Total Non Current Liabilities Net Minority Interest | $14,475,000 | $16,883,000 | $13,439,000 | $12,811,000 |
| Current Liabilities | $20,414,000 | $27,450,000 | $24,373,000 | $16,547,000 |
| Other Current Liabilities | $217,000 | $416,000 | $665,000 | $750,000 |
| Payables And Accrued Expenses | $11,919,000 | $14,926,000 | $15,161,000 | $10,531,000 |
| Payables | $5,344,000 | $4,602,000 | $5,450,000 | $3,339,000 |
| Total Tax Payable | $3,377,000 | $0 | - | $50,000 |
| Accounts Payable | $1,967,000 | $4,602,000 | $5,450,000 | $3,339,000 |
| Equity | ||||
| Common Stock Equity | $303,132,000 | $571,553,000 | $332,213,000 | $277,423,000 |
| Total Equity Gross Minority Interest | $303,132,000 | $571,553,000 | $332,213,000 | $277,423,000 |
| Stockholders Equity | $303,132,000 | $571,553,000 | $332,213,000 | $277,423,000 |
| Retained Earnings | $-481,765,000 | $-568,779,000 | $-381,426,000 | $-228,434,000 |
| Other | ||||
| Treasury Shares Number | $21,126,760 | - | $0 | - |
| Ordinary Shares Number | $19,543,706 | $40,554,705 | $31,841,084 | $27,543,453 |
| Share Issued | $40,670,466 | $40,554,705 | $31,841,084 | $27,543,453 |
| Tangible Book Value | $303,132,000 | $571,553,000 | $332,213,000 | $277,423,000 |
| Invested Capital | $303,132,000 | $571,553,000 | $332,213,000 | $277,423,000 |
| Working Capital | $295,020,000 | $561,443,000 | $322,920,000 | $269,220,000 |
| Capital Lease Obligations | $16,883,000 | $18,861,000 | $14,444,000 | $13,266,000 |
| Total Capitalization | $303,132,000 | $571,553,000 | $332,213,000 | $277,423,000 |
| Treasury Stock | $384,558,000 | $0 | - | - |
| Additional Paid In Capital | $1,169,451,000 | $1,140,328,000 | $713,636,000 | $505,855,000 |
| Capital Stock | $4,000 | $4,000 | $3,000 | $2,000 |
| Common Stock | $4,000 | $4,000 | $3,000 | $2,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $14,475,000 | $16,883,000 | $13,439,000 | $12,811,000 |
| Current Capital Lease Obligation | $2,408,000 | $1,978,000 | $1,005,000 | $455,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,870,000 | $10,130,000 | $7,542,000 | $4,811,000 |
| Current Accrued Expenses | $6,575,000 | $10,324,000 | $9,711,000 | $7,192,000 |
| Net PPE | $21,138,000 | $23,488,000 | $19,468,000 | $17,569,000 |
| Accumulated Depreciation | $-4,435,000 | $-2,949,000 | $-1,720,000 | $-1,163,000 |
| Gross PPE | $25,573,000 | $26,437,000 | $21,188,000 | $18,732,000 |
| Other Properties | $24,274,000 | $25,229,000 | $20,613,000 | $18,200,000 |
| Machinery Furniture Equipment | $1,299,000 | $1,208,000 | $575,000 | $319,000 |
| Leases | - | - | $0 | $213,000 |
| Properties | - | - | $0 | $0 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $105,954,000 | $-162,800,000 | $-126,972,000 | $-71,303,000 |
| Operating Activities | ||||
| Operating Cash Flow | $107,505,000 | $-160,869,000 | $-124,508,000 | $-70,062,000 |
| Cash Flow From Continuing Operating Activities | $107,505,000 | $-160,869,000 | $-124,508,000 | $-70,062,000 |
| Operating Gains Losses | $-13,000 | - | $4,000 | $12,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,551,000 | $-1,931,000 | $-2,464,000 | $-1,241,000 |
| Investing Cash Flow | $-1,551,000 | $-1,931,000 | $-2,464,000 | $-1,241,000 |
| Cash Flow From Continuing Investing Activities | $-1,551,000 | $-1,931,000 | $-2,464,000 | $-1,241,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-375,000,000 | $0 | - | - |
| Issuance Of Capital Stock | $0 | $380,134,000 | $175,825,000 | $119,578,000 |
| Financing Cash Flow | $-378,470,000 | $391,821,000 | $178,956,000 | $120,309,000 |
| Cash Flow From Continuing Financing Activities | $-378,470,000 | $391,821,000 | $178,956,000 | $120,309,000 |
| Net Other Financing Charges | $-3,758,000 | $-454,000 | $-94,000 | $-87,000 |
| Net Common Stock Issuance | $-375,000,000 | $380,134,000 | $175,825,000 | $119,578,000 |
| Common Stock Issuance | $0 | $380,134,000 | $175,825,000 | $119,578,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Income Tax Paid Supplemental Data | $7,145,000 | $0 | - | - |
| End Cash Position | $288,864,000 | $561,380,000 | $332,359,000 | $280,375,000 |
| Beginning Cash Position | $561,380,000 | $332,359,000 | $280,375,000 | $231,369,000 |
| Changes In Cash | $-272,516,000 | $229,021,000 | $51,984,000 | $49,006,000 |
| Proceeds From Stock Option Exercised | $288,000 | $12,141,000 | $3,225,000 | $818,000 |
| Common Stock Payments | $-375,000,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-1,551,000 | $-1,931,000 | $-2,464,000 | $-1,241,000 |
| Purchase Of PPE | $-1,551,000 | $-1,931,000 | $-2,464,000 | $-1,241,000 |
| Change In Working Capital | $-12,111,000 | $-11,437,000 | $-2,650,000 | $14,308,000 |
| Change In Other Working Capital | $-1,978,000 | $-1,320,000 | $384,000 | $-3,711,000 |
| Change In Other Current Assets | $2,056,000 | $-4,000 | $-478,000 | $-1,574,000 |
| Change In Payables And Accrued Expense | $-13,132,000 | $2,703,000 | $6,871,000 | $4,914,000 |
| Change In Accrued Expense | $-10,131,000 | $2,952,000 | $5,257,000 | $5,322,000 |
| Change In Payable | $-3,001,000 | $-249,000 | $1,614,000 | $-408,000 |
| Change In Account Payable | $-3,001,000 | $-249,000 | $1,614,000 | $-408,000 |
| Change In Prepaid Assets | $4,018,000 | $-10,217,000 | $-9,284,000 | $-3,321,000 |
| Change In Receivables | $-3,075,000 | $-2,599,000 | $-143,000 | $18,000,000 |
| Changes In Account Receivables | $-825,000 | $-2,599,000 | $-143,000 | $18,000,000 |
| Other Non Cash Items | $2,410,000 | $1,820,000 | $1,552,000 | $941,000 |
| Stock Based Compensation | $28,696,000 | $34,872,000 | $28,763,000 | $18,682,000 |
| Depreciation Amortization Depletion | $1,509,000 | $1,229,000 | $815,000 | $674,000 |
| Depreciation And Amortization | $1,509,000 | $1,229,000 | $815,000 | $674,000 |
| Depreciation | $1,509,000 | $1,229,000 | $815,000 | $674,000 |
| Gain Loss On Sale Of PPE | $-13,000 | $0 | $4,000 | $12,000 |
| Net Income From Continuing Operations | $87,014,000 | $-187,353,000 | $-152,992,000 | $-104,679,000 |
| Change In Other Current Liabilities | - | - | $0 | $0 |
Fetched: 2026-06-22